Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 15;14(1):603-611.
eCollection 2022.

Rectal administration of Panax notoginseng and Colla Corii Asini suppositories in ulcerative colitis: clinical effect and influence on immune function

Li Zeng  1 , Xiaohai Li  1 , Guomin Bai  1 , Yu Liu  1 , Qingge Lu  2
Affiliations

Rectal administration of Panax notoginseng and Colla Corii Asini suppositories in ulcerative colitis: clinical effect and influence on immune function

Li Zeng et al. Am J Transl Res. .

Abstract

Objective: This study was designed to evaluate the efficacy of rectal administration of different doses of Panax notoginseng and Colla Corii Asini (CCA) suppositories in the treatment of ulcerative colitis (UC) and the effect on immune function and recurrence.

Methods: Totally 120 UC patients admitted to our hospital from February 2019 to February 2020 were enrolled and randomized into experimental group (n=60) and control group (n=60). The experimental group received rectal administration of a high dose of Panax notoginseng and CCA suppositories, while the control group received a low dose. After three months of treatment, clinical symptom scores, inflammatory factor levels, scores of rectal mucosa, immune function, recurrence rates, adverse reaction rates, and clinical efficacy were compared between the two groups.

Results: After treatment, the experimental group obtained significantly lower clinical symptom scores, inflammatory factors, and scores of rectal mucosa than the control group (all P<0.001). The immune function of the observation group was significantly better than that of the control group (P<0.001). At 6, 8, and 12 months after treatment, the recurrence rates in the experimental group were all significantly lower than those in the control group (all P<0.001). The two groups showed no significant difference in the incidence of adverse reaction (P>0.05), and the experimental group obtained a higher clinical efficacy than the control group (P<0.001).

Conclusion: For patients with UC, the rectal administration of Panax notoginseng and CCA suppositories can exert positive effects on their inflammatory factors, immune functions, UC severity, clinical symptoms, and recovery. In addition, higher doses were associated with better effects without increased adverse events.

Keywords: Panax notoginseng and Colla Corii Asini suppositories; rectal administration; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Comparison of clinical symptom scores between the two groups of patients. A: Diarrhea symptom scores; B: Purulent and bloody stool symptom scores. ***, P<0.001.
Figure 2
Figure 2
Comparison of inflammatory factors between the two groups of patients. A: Serum level of IL-6; B: Serum level of IL-23. ***, P<0.001.
Figure 3
Figure 3
Comparison of scores of rectal mucosa between the two groups of patients. Notes: ***, P<0.001.
Figure 4
Figure 4
Immune function determined using the flow cytometry.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Graziano F, Macaluso FS, Cassata N, Citrano M, Orlando A. Pyoderma gangrenosum in an UC pediatric patient during vedolizumab therapy successfully treated with oral cyclosporine. Inflamm Bowel Dis. 2021;27:e110–e111. - PubMed
    1. Bossuyt P, Vermeire S, Bisschops R. Assessing disease activity in UC using artificial intelligence: can “equally good” be seen as “better”? Gastroenterology. 2020;159:1625–1626. - PubMed
    1. Hoffmann P, Globig AM, Thomann AK, Grigorian M, Krisam J, Hasselblatt P, Reindl W, Gauss A. Tofacitinib in treatment-refractory moderate to severe UC: real-world experience from a retrospective multicenter observational study. J Clin Med. 2020;9:2177. - PMC - PubMed
    1. Fudman DI, Sattler L, Feuerstein JD. Inpatient management of acute severe UC. J Hosp Med. 2019;14:766–773. - PubMed
    1. Kotwani P, Terdiman J, Lewin S. Tofacitinib for rescue therapy in acute severe uc: a real-world experience. J Crohns Colitis. 2020;14:1026–1028. - PubMed

LinkOut - more resources